Get Connected:


Latest News

Common Cold Virus: A Potential Immunotherapy for Liver Diseases
Reovirus may treat primary liver cancer and hepatitis C virus.
Ninlaro regimen increased progression-free survival by 40% in patients with multiple myeloma.
Patients with addiction or mental health conditions may benefit from treatment with marijuana.
A diagnostic diabetes breathalyzer may one day become a reality.
FDA approvea Relypsa, Inc.’s supplemental New Drug Application with label updates of Veltassa.
Phase 3 trials showed that empaglifloxin can reduce blood pressure in type 2 diabetes patients.
The For Your Sweetheart campaign aims to improve education about the link between heart disease and diabetes.
Unsealed court testimony emphasizes the problems with the merger among healthcare giants.
View More >

From the Journals

This study explores the impact of a Medicare Part D formulary tier change, specifically with respect to branded insulin products, on insulin adherence, hemoglobin A1C, and diabetes-related events in elderly diabetic beneficiaries strategies for selection of appropriate and cost-effective therapy will also be discussed.
This study assesses comparative resource use for patients given a new diagnosis of nonvalvular atrial fibrillation treated with dabigatran or warfarin in a real-world setting.
This retrospective study compared the treatment patterns of ustekinumab with recommended maintenance administration every 12 weeks, with adalimumab and etanercept, administered weekly or every other week, for the treatment of plaque psoriasis.
This study presents the first information available regarding enablement and use by state and area characteristics of electronic prescribing of controlled substances by prescribers and pharmacy systems in from an e-prescribing network.
This manuscript addresses pharmacist understanding of and/or involvement with the Hospital-Acquired Condition Reduction Program (HACRP) at their institutions.
The role of Pharmacy and Therapeutic committees in formulary creations raises concerns.
This study examines variations in overall use, and potentially inappropriate use, of non-warfarin direct-acting oral anticoagulants across sites within the Veterans Health Administration.
Upcoming Partner Events